KRAS and colorectal carcinoma: In addition, mutations in the extracellular domain of EGFR or upregulation of alternative EGFR ligands amphiregulin and epiregulin are likely mechanisms of anti-EGFR therapy resistance in KRAS-WT CRC patients [41].